Involvement of Eotaxins (CCL11, CCL24, CCL26) in Pathogenesis of Osteopenia and Osteoporosis

The purpose of this study was to investigate the role of eotaxin family members including C-C motif chemokine 11 (CCL11), C-C motif chemokine 24 (CCL24), and C-C motif chemokine 26 (CCL26) as the subgroups of CC-chemokine in patients affected with osteoporosis and osteopenia. Overall, 19 osteoporoti...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of public health 2020-09, Vol.49 (9), p.1769-1775
Main Authors: Ahmadi, Hadis, Khorramdelazad, Hossein, Hassanshahi, Gholamhossein, Abbasi Fard, Mitra, Ahmadi, Zahra, Noroozi Karimabad, Mojgan, Mollahosseini, Majid
Format: Article
Language:English
Subjects:
Biomedical materials
Bone density
Bone mineral density
Chemokines
Dual energy X-ray absorptiometry
Enzyme-linked immunosorbent assay
Eotaxin
Eotaxins
Hip
Human
Original
Osteopenia
Osteoporosis
Pathogenesis
Protein
Serum levels
Spine
Spine (lumbar)
Subgroups
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to investigate the role of eotaxin family members including C-C motif chemokine 11 (CCL11), C-C motif chemokine 24 (CCL24), and C-C motif chemokine 26 (CCL26) as the subgroups of CC-chemokine in patients affected with osteoporosis and osteopenia. Overall, 19 osteoporotic patients, 18 osteopenic individuals, and 20 healthy subjects were recruited in this study. The bone mineral density (BMD) was then measured at the lumbar spine (L1-L4) and the hip (femoral neck and total hip) using dual-energy X-ray absorptiometry for diagnosis of bone density and related disorders. Additionally, enzyme-linked immunosorbent assay (ELISA) technique was employed to measure the serum levels of CCL11, CCL24, and CCL26. The circulating levels of CCL11, CCL24, and CCL26 had been increased in both groups of patients with osteopenia and osteoporosis compared to those in healthy subjects (
ISSN:2251-6085
2251-6093
DOI:10.18502/ijph.v49i9.4098